Results 81 to 90 of about 2,780 (214)

Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms [PDF]

, 2017
Psilocybin with psychological support is showing promise as a treatment model in psychiatry but its therapeutic mechanisms are poorly understood.
Bolstridge, Mark, Carhart-Harris, Robin L, Curran, H Valerie, Demetriou, Lysia, Kaelen, Mendel, Leech, Robert, McGonigle, John, Murphy, Kevin, Nutt, David J, Pannekoek, J Nienke, Roseman, Leor, Tanner, Mark, Wall, Matthew B   +12 more
core   +4 more sources

Evidence that 5‐HT2A receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non‐psychedelic drugs

British Journal of Pharmacology, EarlyView.
Background and Purpose Serotonergic psychedelic drugs are under investigation as therapies for various psychiatric disorders, including major depression. Although serotonergic psychedelic drugs are 5‐HT2A receptor agonists, some such agonists are not psychedelic, potentially due to differences in 5‐HT2A receptor ligand bias or signalling efficacy. Here,
Aurelija Ippolito, Sridhar Vasudevan, Shaun Hurley, Gary Gilmour, Frederick Westhorpe, Grant Churchill, Trevor Sharp   +6 more
wiley   +1 more source

Psilocybin Use in an Intercollegiate Athlete with Persisting Symptoms After Concussion: A Case Report

Psychoactives
Background: Persisting symptoms after concussion is a complex syndrome warranting exploration into further treatment options. Emerging research highlights the potential of classic psychedelics, such as psilocybin, in managing neuropsychiatric conditions ...
David W. Lawrence, Alex P. Di Battista, Michael G. Hutchison   +2 more
doaj   +1 more source

Novel Psychoactive Substances 14Recent Progress on Neuropharmacological Mechanisms of Action for Selected Drugs [PDF]

, 2017
A feature of human culture is that we can learn to consume chemical compounds, derived from natural plants or synthetic fabrication, for their psychoactive effects.
Boris B. , Quednow, Christian P. , Müller, Erich, Seifritz, Hassan, Zurina, Johannes, Kornhuber, Kasinather, B. Vicknasingam, Narayanan, Suresh, Oliver G., Bosch, Singh, Darshan   +8 more
core   +1 more source

Are we hallucinating or can psychedelic drugs modulate the immune system to control inflammation?

British Journal of Pharmacology, EarlyView.
Psychedelic drugs that activate 5‐HT2A receptors have been long used for cultural, medicinal and recreational purposes. Interest in psychedelics for treating psychiatric disorders has resurged recently and is well documented; less well recognised are their anti‐inflammatory properties. Growing evidence now demonstrates that psychedelics modulate immune
Omar Qureshi, Jamie Cowley, Ashley Pegg, Alison J. Cooper, John Gordon, Catherine A. Brady, Antonio Belli, Sam Butterworth, Rachel Upthegrove, Nick Andrews, Nicholas M. Barnes   +10 more
wiley   +1 more source

Effects of hallucinogenic drugs on the human heart

Frontiers in Pharmacology
Hallucinogenic drugs are used because they have effects on the central nervous system. Their hallucinogenic effects probably occur via stimulation of serotonin receptors, namely, 5-HT2A-serotonin receptors in the brain.
Joachim Neumann, Stefan Dhein, Uwe Kirchhefer, Britt Hofmann, Ulrich Gergs   +4 more
doaj   +1 more source

Novel psychoactive substances of interest for psychiatry [PDF]

, 2015
Novel psychoactive substances include synthetic cannabinoids, cathinone derivatives, psychedelic phenethylamines, novel stimulants, synthetic opioids, tryptamine derivatives, phencyclidine-like dissociatives, piperazines, GABA-A/B receptor agonists, a ...
Corkery, John, Orsolini, Laura, Papanti, Duccio, Schifano, Fabrizio   +3 more
core   +1 more source

Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology

British Journal of Pharmacology, EarlyView.
Theorized mechanism of dopamine homeostasis restoration in the nucleus accumbens core induced by a psychedelic intervention. Abstract Psychedelics have garnered great attention in recent years as treatments for major depressive disorder (MDD) and treatment‐resistant depression because of their ability to alter consciousness and afflicted cognitive ...
Lucas Wittenkeller, Gary Gudelsky, T. John Winhusen, Davide Amato   +3 more
wiley   +1 more source

Modern Clinical Research on LSD [PDF]

, 2017
All modern clinical studies using the classic hallucinogen lysergic acid diethylamide (LSD) in healthy subjects or patients in the last 25 years are reviewed herein. There were five recent studies in healthy participants and one in patients.
A Garcia-Romeu, A Rickli, A Rickli, AB Wolbach Jr, AL Halberstadt, AL Halberstadt, Andrea E. Steuer, AV Lebedev, CM Hysek, CM Hysek, CS Grob, D Holland, D Marona-Lewicka, D Nutt, DB Terhune, DE Nichols, DE Nichols, DE Nichols, DV Sheehan, E Gouzoulis-Mayfrank, E Studerus, E Tagliazucchi, EA Schindler, F Hasler, F Mueller, FL Osorio, FX Vollenweider, FX Vollenweider, J Riba, J Seibert, J Speth, JC Bouso, JH Halpern, JJ Rucker, KA MacLean, KH Preller, KH Preller, KH Preller, KPC Kuypers, L Roseman, L Roseman, LD Simmler, LE Hollister, M Johnson, M Kaelen, M Kaelen, M Kometer, M Kometer, MA Geyer, Matthias E Liechti, ME Liechti, MJ Baggott, MP Bogenschutz, MW Johnson, P Gasser, P Gasser, P Strajhar, Patrick C. Dolder, PC Dolder, PC Dolder, PC Dolder, PS Hendricks, R Kraehenmann, Rainer Kraehenmann, RE Belleville, RG Dos Santos, RJ Strassman, RJ Strassman, RL Carhart-Harris, RL Carhart-Harris, RL Carhart-Harris, RL Carhart-Harris, RL Carhart-Harris, RL Carhart-Harris, RL Carhart-Harris, RR Griffiths, RR Griffiths, S Ross, SD Muthukumaraswamy, T Passie, TS Krebs, TS Krebs, WE Fantegrossi, WN Pahnke, WN Pahnke, Y Schmid   +85 more
core   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source